Physician profile
Mohammad S Arain
NPI 1114909199
$742.86
in general payments reported to CMS, 2019-2025
15 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Adolescent Medicine (Family Medicine) provider received nationally (typical 2025 total: $135).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.84 · 2020: $153 · 2021: $73.74 · 2022: $151 · 2023: $184 · 2024: $30.69 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.95 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.10 | 2020-2023 | Bexsero, Pediarix, Rotarix |
| Novo Nordisk INC | $108.58 | 2020-2023 | Wegovy, Saxenda |
| Supernus Pharmaceuticals, INC. | $91.56 | 2025 | Qelbree |
| Pfizer INC. | $58.84 | 2019-2024 | |
| Lilly USA, LLC | $58.51 | 2020 | |
| Sanofi Pasteur INC. | $56.38 | 2022-2025 | |
| Seqirus USA INC | $46.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $42.84 | 2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $39.33 | 2019-2023 | Vaqta, Gardasil 9, Vaxelis |
| Tris Pharma INC | $22.60 | 2020 | |
| Abbott Laboratories | $21.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.99 | 2020 | |
| Inari Medical, INC. | $14.17 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Corium, LLC | $13.70 | 2023 | Azstarys |
| Adlon Therapeutics L.P. | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Arain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.